Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 18;23(9):6060–6071. doi: 10.1111/jcmm.14469

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

EIF2A promotes cell survival during paclitaxel treatment in vivo. A, B and C, Size and weight of xenograft tumours formed by MDA‐MB‐231 derivatives including a doxycycline‐inducible shRNA targeting EIF2A and scramble shRNA. Each group was treated as indicated. Data are mean ± SEM **P < 0.01. D, Immunohistochemical analyses of the expression of EIF2A and p‐EIF2S1 in xenograft tumours as described above. E, Immunohistochemical analyses of patient samples for p‐EIF2S1 levels in patients. Top: paracentesis specimens before treatment. Bottom: surgical specimens after paclitaxel‐based neoadjuvant chemotherapy. F, Immunohistochemical analysis was graded on a scale of 1‐3 according to staining intensity. Specimens form 30 patients participated in the statistic. Paired t test was used for calculating statistical significance. G, Probability of relapse‐free survival in 3955 breast cancer patients stratified on low (black) versus high (red) expression levels of indicated genes was obtained from Kaplan‐Meier Plotter/breast cancer (http://www.kmplot.com)